Back to Search Start Over

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

Authors :
Etemadmoghadam D
Azar WJ
Lei Y
Moujaber T
Garsed DW
Kennedy CJ
Fereday S
Mitchell C
Chiew YE
Hendley J
Sharma R
Harnett PR
Li J
Christie EL
Patch AM
George J
Au-Yeung G
Mir Arnau G
Holloway TP
Semple T
Pearson JV
Waddell N
Grimmond SM
Köbel M
Rizos H
Lomakin IB
Bowtell DDL
deFazio A
Source :
Cancer research [Cancer Res] 2017 Aug 15; Vol. 77 (16), pp. 4268-4278. Date of Electronic Publication: 2017 Jun 23.
Publication Year :
2017

Abstract

Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and are molecularly characterized by RAS pathway activation. Using exome and whole genome sequencing, we identified recurrent mutations in the protein translational regulator EIF1AX and in NF1, USP9X, KRAS, BRAF , and NRAS RAS pathway mutations were mutually exclusive; however, we found significant co-occurrence of mutations in NRAS and EIF1AX Missense EIF1AX mutations were clustered at the N-terminus of the protein in a region associated with its role in ensuring translational initiation fidelity. Coexpression of mutant NRAS and EIF1AX proteins promoted proliferation and clonogenic survival in LGSC cells, providing the first example of co-occurring, growth-promoting mutational events in ovarian cancer. Cancer Res; 77(16); 4268-78. ©2017 AACR .<br /> (©2017 American Association for Cancer Research.)

Details

Language :
English
ISSN :
1538-7445
Volume :
77
Issue :
16
Database :
MEDLINE
Journal :
Cancer research
Publication Type :
Academic Journal
Accession number :
28646021
Full Text :
https://doi.org/10.1158/0008-5472.CAN-16-2224